Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKE

Riociguat is an sGC stimulator currently approved and marketed for pulmonary arterial hypertension.

Propylthiouracil, already marketed for the treatment of various subtypes of hyperthyroidism, has been identified as a new member of the class of potent and effective neuronal nitric oxide synthase (NOS1) inhibitors

Perphenazine, already marketed as an antiemetic and antipsychotic drug, presents the best NADPH oxidase (NOX) inhibitory characteristics compared to other compounds of the same drug class.